ImmunoGen, Inc. (NASDAQ: IMGN) shares fell 15.66
percent to touch a new 52-week low of $4.18 after the company announced a private offering of $100 million in convertible senior
notes.
Infinity Pharmaceuticals Inc. (NASDAQ: INFI)
shares dropped 67.35 percent to touch a new 52-week low of $1.44. Infinity announced plans to cut 21 percent of the workforce. The
company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary
endpoint.
Revance Therapeutics Inc (NASDAQ: RVNC) shares
reached a new 52-week low of $13.77 as the company reported that its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel
(RT001) to treat patients with moderate to severe lateral canthal lines (crow's feet) had failed to meet co-primary and other
endpoints.
KemPharm Inc (NASDAQ: KMPH) shares fell 21.62
percent to touch a new 52-week low of $4.93 after the company reported that it has received a Complete Response Letter from the FDA
regarding its Apadaz NDA .
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.